Influence of Glucose on Metabolism and Clinical Symptoms of Patients With Parkinson's Disease

Más betegség

• Other significant neurological diseases primarily affecting the central nervous system (e.g., multiple sclerosis)
• Diagnosis of diabetes mellitus or prediabetes
• cardiac or brain pacemakers

Laborértékek

• Use of medications that affect glucose metabolism, such as antidiabetics, glucocorticoids, ciclosporin, tacrolimus, sirolimus, beta-blockers, thiazide diuretics, beta-2 adrenoreceptor agonists, theophylline, Clozapine, olanzapine, paliperidone, quetiapine, risperidone, tricyclic antidepressants, mirtazapine, mianserin, carbamazepine, gabapentin, pregabalin, valproic acid, lithium, antiretroviral drugs, statins

• Diagnosis of Parkinson's Disease, stage Hoehn \& Yahr 1.5-3
• Ability to pause antiparkinsonian medication in the morning without relevant impairment
• Capacity to give consent (determined in doubt by two independent neurologists, MOCA ≥18) and written informed consent.
• Patients are between 50 and 80 years of age, with exceptions for a maximum of 5 additional patients enrolled per group
• For stratification into patients with and without sweet craving, a 3-day dietary protocol should be completed once by the patients
• Group I: increased hunger for sweets.
• Group II: no increased hunger for sweets.
  • For the stratification into patients with and without increased hunger for sweets, participants are asked to answer the following questions:
• Do you have sudden attacks of cravings for sweets?
• Would you say that your consumption of sweet food has increased in recent years?
• Would you describe your consumption of sugary food as increased or excessive?
  • If one of the questions is answered with yes, participants will be assigned to group I, if all questions are answered with no, participants will be assigned to group II.